Bayer’s Xarelto® Approved in the EU for Secondary Prevention after an
- ICU
- 29/05/2013
Following an ACS event, one in ten patients will have another major atherothrombotic event (cardiovascular death, myocardial infarction or stroke) within a year / Xarelto 2.5 mg BID in combinatio
READ MORE